To determine whether the PRL-LFPRLR axis elevates the risk of establishment of overt B-cell malignancies from pre-malignant B cells, we compared B-cell pathology in DLBCL-prone CD79b-TCL1-tg mice28, treated with either control SMO or LFPRLR SMO. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.